Literature DB >> 19352606

[Testis cancer: the UK as a model].

S B Maddineni1, N W Clarke.   

Abstract

Over the course of the past 30 years progress in identification of risk factors, improvements in therapy regimens and advances in treatment delivery have all served to render testis cancer a treatable and survivable malignancy. Institution of specialised oncology centres in the UK to address treatment options for urological cancers has proven to be an effective approach to managing testis cancer by drawing on interdisciplinary expertise and applying insights gained from ongoing R&D. This strategy could become a model for treating other cancers as well.

Entities:  

Mesh:

Year:  2009        PMID: 19352606     DOI: 10.1007/s00120-009-1949-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  22 in total

1.  Assessing the size and stage of testicular germ cell tumours: 1984-2003.

Authors:  Jeetesh M Bhardwa; Tom Powles; Dan Berney; Suhail Baithun; Vinod H Nargund; R Tim D Oliver
Journal:  BJU Int       Date:  2005-10       Impact factor: 5.588

2.  Geographical variation in mortality from conditions amenable to medical intervention in England and Wales.

Authors:  J R Charlton; R M Hartley; R Silver; W W Holland
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

3.  Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone.

Authors:  L S Freedman; M C Parkinson; W G Jones; R T Oliver; M J Peckham; G Read; E S Newlands; C J Williams
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

4.  Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.

Authors:  J R Spermon; T A Roeleveld; H G van der Poel; C A Hulsbergen-van de Kaa; W W Ten Bokkel Huinink; M van de Vijver; J A Witjes; S Horenblas
Journal:  Urology       Date:  2002-06       Impact factor: 2.649

5.  Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival.

Authors:  C S McArdle; D Hole
Journal:  BMJ       Date:  1991-06-22

6.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

7.  Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.

Authors:  N Aass; O Klepp; E Cavallin-Stahl; O Dahl; H Wicklund; B Unsgaard; L Baldetorp; S Ahlström; S D Fosså
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

8.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

Review 9.  Part I: testicular cancer--management of early disease.

Authors:  Robert H Jones; Paul A Vasey
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

10.  Survival from testicular cancer in England and Wales up to 2001.

Authors:  R A Huddart
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.